Raymond Chow joins the Novo Holdings Advisory Group 

Raymond Chow will be supporting Novo Holdings’ Asia investment activities. 

Novo Holdings is pleased to announce the appointment of Raymond Chow to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments.  

Raymond Chow has more than 28 years of experience in healthcare and life sciences, with regional leadership roles spanning Southeast Asia, India, Korea, Japan, Australia, New Zealand, Taiwan, Hong Kong and China. With his appointment, the NAG is strengthening its commercial, operational and market development expertise in relation to its Asia investment activities. 

Kasim Kutay, CEO of Novo Holdings, said: “Raymond brings valuable know-how and insights pertaining to the key markets and subsectors most relevant to our Asia strategy. I very much look forward to working with him.”  

Building and scaling healthcare businesses across Asia 
Raymond Chow has deep expertise in medical technology, life science tools and diagnostics, bioprocessing and pharmaceutical systems, while bringing a strong commercial, operational and market development perspective. 

Most recently, he served as Vice President, Asia Pacific at Cytiva, a global leader supporting biopharma research, clinical development and commercial manufacturing, where he led regional strategy, commercial growth and operational excellence. 

Before joining Cytiva, he spent sixteen years with BD (Becton Dickinson), holding executive leadership appointments including as Vice President for Central Asia and Vice President for Pharmaceutical Systems, Greater Asia.  

Earlier in his career, Raymond Chow held leadership roles at GE Healthcare, where he led the Interventional Cardiology and Surgery business across Southeast Asia, as well as at Boston Scientific and Philips Healthcare. 

Raymond Chow said: “It is an honour to be appointed to the Novo Advisory Group. I look forward to drawing on my experience from building healthcare businesses across Asia to support Novo Holdings’ mission as a life science investor.” 

About Raymond Chow 
Singapore citizen 

Career 
2024 – 2026 Vice President, Asia Pacific, Cytiva, Singapore 

2019 – 2024 Vice President, Central Asia, BD (Becton Dickinson), Singapore 

2016 – 2024 Vice President, Pharmaceutical Systems, Greater Asia, BD, Singapore 

2012 – 2016 Business Director, BD Biosciences, Central and South Asia, Singapore 

2010 – 2012 Business Director, BD Biosciences – Discovery Labware & Advanced Bioprocessing, Asia Pacific, Singapore 

2008 – 2010 Business Manager, BD Biosciences, Southeast Asia, Singapore 

2006 – 2008 Modality Manager, GE Healthcare, Singapore 

2004 – 2006 Business Development Manager, Boston Scientific, Singapore 

1997 – 2003 Account Manager, Philips Healthcare, Singapore 

Education 
Raymond holds a Bachelor of Engineering in Electronics from the University of South Australia and a Doctorate in Business Administration from European Institute of Management and Technology (EIMT).